GLP3-R + GLP4-C Blend is a research-market compounded peptide product combining retatrutide (a triple GIP/GLP-1/glucagon receptor agonist in Phase III development) with a second component vendor-labeled as 'GLP4-C'. The 'GLP4-C' designation is not a recognized scientific or clinical compound name and its molecular identity varies between vendors. No human trials of this blend exist, no clinical efficacy data are available, and the mechanistic rationale is uncertain beyond the retatrutide component. Sold strictly as a research chemical without independent verification of the second component's identity.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Formulation caution
'GLP4-C' is a research-market designation, not a recognized clinical compound. Second component is unidentified in the index. Surface this clearly on the detail page.
What's in this blend
Unidentified components
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
The retatrutide component is a long-acting peptide triple agonist of the GIP, GLP-1, and glucagon receptors. GLP-1 signaling drives appetite suppression, slowed gastric emptying, and glucose-dependent insulin secretion; GIP contributes to insulin release and adipose handling; glucagon receptor activation increases hepatic lipolysis and energy expenditure (Jastreboff et al.
Pharmacokinetic properties
Half-life
Retatrutide ~6 days subcutaneous; 'GLP4-C' PK is undocumented since the compound identity is uncertain.
Routes
subcutaneous
Bioavailability
Both components are presumed peptides without oral bioavailability.
Amino-acid sequence
Use & research dosing
No clinical evidence supports any specific dosing schedule for this blend. Self-experimentation protocols typically follow standard retatrutide titration (~2 mg weekly increasing to 8-12 mg) with the second component dosed per vendor labeling, which itself is not standardized. Not FDA-approved, not in any registered trial, and not pharmacokinetically characterized as a combination. Research framing only — no clinical dose recommendation.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Current state: This product is mechanistically and identity-wise problematic. The 'GLP4-C' label has no scientific definition, and stacking multiple incretin agonists produces redundant rather than complementary receptor activation. No clinical trial of the blend exists. Buyers cannot independently verify what the second peptide actually is. The honest assessment is that this is a vendor-defined product without scientific support beyond the retatrutide component.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.